Milestone Pharmaceuticals Inc. (NASDAQ:MIST) will release earnings for its fourth quarter before the opening bell on Friday, March 20.
Analysts expect the Montreal, Canada-based company to report a quarterly loss of 16 cents per share on revenue of $1.20 million, according to Benzinga Pro.
On Feb. 10, Milestone Pharmaceuticals named David Sandoval as general counsel and chief compliance officer.
Shares of Milestone Pharmaceuticals closed at $1.70 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- HC Wainwright & Co. analyst Brandon Folkes maintained a Buy rating with a price target of $8 on Jan. 6, 2026. This analyst has an accuracy rate of 46%.
- Wells Fargo analyst Mohit Bansal maintained an Overweight rating and increased the price target from $4 to $8 on Dec. 16, 2025. This analyst has an accuracy rate of 68%.
- TD Cowen analyst Ritu Baral upgraded the stock from Hold to Buy with a price target of $8 on Dec. 15, 2025. This analyst has an accuracy rate of 49%.
Considering buying MIST stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments